Chunk #12 — 3. Pharmacogenetic Studies of Treatment for Alcohol Use Disorder in Individuals of Diverse Ancestries — 3.1 Individuals of European Ancestry
These results, however, are inconsistent with additional reports that found no association between the OPRM1 Asn40Asp polymorphism and response to NTX in primarily European-American samples.31, 34 In a study conducted by Gelernter et al., only males who participated in a Veterans Affairs Cooperative Study were recruited.31 They found that there were no interactions between treatment response and genotype. It is possible, however, that this population is unique in regards to the frequency of comorbidities present among individuals, which may have been a confounding variable. For example, within the sample for which they received genotype data, 1.5% of the military participants had a psychiatric disability unrelated to AUD, 16.8% had a medical disability unrelated to AUD, and 15% of nonmilitary participants had either a psychiatric or medical disability unrelated to AUD. Furthermore, while the majority of this sample was comprised of European Americans (73.6%), African Americans accounted for the other 24.4%, which may have also skewed the results. Similarly, the study by Arias et al. recruited veterans who, in addition to being AD, had also been diagnosed with a mood, anxiety,
